Skip to Content
  • AstraZeneca Gets the Bad News

    After writing about Merck’s successes (so far) in immuno-oncology, it’s time to write about AstraZeneca’s failure. When the rumors started fly… Read More
  • The Keytruda Story

    This is a good history of Keytruda, the Merck immuno-oncology blockbuster, from David Shaywitz. Most big drugs have a tangled history, and this one is certainly… Read More
  • Too Big to Be True

    I recently wrote a column for Chemistry World on the concept of effect size – the readership there is from all sorts of chemistry, so it’s perhaps n… Read More
  • Chaos at AstraZeneca

    What on earth is going on over at AstraZeneca? The company has had plenty of wild ups and downs over the years, and managed to fight off a takeover attempt by P… Read More
  • A Heroin Vaccine?

    Drug addiction is a terrible public health problem, and a terrible personal problem for anyone facing it. Giving addicts a better chance to break the drug-taki… Read More
  • Two Diabetes Drug Mysteries

    Here are some data to file under “Drugs do things that we don’t expect”. The SGLT-2 inhibitors are a class of diabetes medications that work b… Read More
Page 1 of 4612345...102030...Last »